公开(公告)号：US20170216429A1

公开(公告)日：2017-08-03

申请号：US15501271

申请日：2015-08-04

Applicant: NITTO DENKO CORPORATION

Inventor： Takuya SHISHIDO ,  Daisuke ASARI ,  Kyohei MATSUSHITA ,  Mitsuhiko HORI

IPC: A61K39/39

CPC classification number: A61K39/39 ,  A61K39/00 ,  A61K2039/54 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/55511 ,  A61K2039/575 ,  Y02A50/388 ,  Y02A50/39

Abstract: The present invention aims to provide a composition for promoting humoral immunity induction and a vaccine pharmaceutical composition that can be universally used for various antigens in inducing humoral immunity to antigens, contain a Th2 reaction promoter, and exerts a high humoral immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition containing an antigen for humoral immunity induction and at least one Th2 reaction promoter.

公开(公告)号：US20160228540A1

公开(公告)日：2016-08-11

申请号：US14916721

申请日：2014-10-02

Applicant: NITTO DENKO CORPORATION

Inventor： Eiji KIYOTOH ,  Mitsuhiko HORI ,  Katsuyuki OKUBO ,  Daisuke ASARI ,  Arimichi OKAZAKI ,  Masahiro FUKASAKA ,  Kyohei MATSUSHITA

IPC: A61K39/39 ,  A61K39/09 ,  A61K39/12 ,  A61K39/15 ,  A61K39/145 ,  A61K39/125 ,  A61K39/165 ,  A61K39/08 ,  A61K39/25 ,  A61K39/205 ,  A61K39/00 ,  A61K39/13

CPC classification number: A61K39/39 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/08 ,  A61K39/092 ,  A61K39/12 ,  A61K39/125 ,  A61K39/13 ,  A61K39/145 ,  A61K39/15 ,  A61K39/165 ,  A61K39/205 ,  A61K39/25 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/543 ,  A61K2039/55572 ,  A61K2039/575 ,  C12N2710/16734 ,  C12N2710/20034 ,  C12N2720/12334 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2760/20134 ,  C12N2770/24134 ,  C12N2770/32434 ,  C12N2770/32634 ,  C12N2770/36234

Abstract: The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively. The present invention provides a nasal mucosal vaccine composition to be administered to a human or animal nasal mucous membrane, the nasal mucosal vaccine composition containing at least one antigen excluding antigens derived from influenza viruses; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.

Abstract translation: 本发明提供一种鼻粘膜疫苗组合物，其是安全的，可用作感染性疾病或癌症的预防或治疗剂，并且能够有效地诱导全身免疫应答和粘膜免疫应答。 本发明提供了向人或动物鼻粘膜施用的鼻粘膜疫苗组合物，所述鼻粘膜疫苗组合物含有至少一种除了源自流感病毒的抗原之外的抗原; 并且作为佐剂，衍生自选自沙雷氏菌属（Salratia），莱克氏菌属（Leclercia），R，属（Rahnella），酸性d螨属（Acidicaldus），酸性，螨属（Acidical il ium，，，era era era era era era era，，，，，，，，Acid Acid Acid Acid as as，As As As ia ia ia ia ia C occus occus occus occus occus，，，ia ia，，，，，，，，，，， （Leahibacter），红球菌属（Myocosococcus），梭状芽孢杆菌属，微球菌属，黄杆菌属，泛菌属，醋杆菌属，发酵单胞菌属，黄单胞菌属，蓝假丝酵母属，蓝假丝酵母属，蓝假丝酵母属， 和肠杆菌属或其盐。

公开(公告)号：US20160213773A1

公开(公告)日：2016-07-28

申请号：US14917077

申请日：2014-10-02

Applicant: NITTO DENKO CORPORATION

Inventor： Masahiro FUKASAKA ,  Mitsuhiko HORI ,  Katsuyuki OKUBO ,  Daisuke ASARI ,  Arimichi OKAZAKI ,  Eiji KIYOTOH ,  Kyohei MATSUSHITA

IPC: A61K39/39 ,  A61K39/09 ,  C12N7/00 ,  A61K39/15 ,  A61K39/13 ,  A61K39/00 ,  A61K39/145 ,  A61K39/12

CPC classification number: A61K39/39 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/092 ,  A61K39/12 ,  A61K39/13 ,  A61K39/145 ,  A61K39/15 ,  A61K2039/52 ,  A61K2039/525 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/544 ,  A61K2039/55572 ,  C12N7/00 ,  C12N2710/20034 ,  C12N2720/12334 ,  C12N2760/16034 ,  C12N2770/32634

Abstract: The present invention aims at providing a vaccine composition capable of being administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is safe, useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and capable of effectively inducing the systemic immune response and mucosal immune response. The present invention provides a mucosal vaccine composition to be administered to at least one mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, the mucosal vaccine composition containing: at least one antigen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof, wherein a mass ratio between the adjuvant and the antigen (total mass of the adjuvant/total mass of the antigen) is 0.002 to 500.

公开(公告)号：US20140220100A1

公开(公告)日：2014-08-07

申请号：US14166952

申请日：2014-01-29

Applicant: NITTO DENKO CORPORATION

Inventor： Katsuyuki OKUBO ,  Yoshiki MAEDA ,  Takuya SHISHIDO ,  Daisuke ASARI ,  Arimichi OKAZAKI ,  Kyohei MATSUSHITA ,  Wenjing LI ,  Mitsuhiko HORI ,  Haruo SUGIYAMA

IPC: A61K39/00

CPC classification number: A61K39/0005 ,  A61K39/0011 ,  A61K2039/54

Abstract: The invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity comprising (i) HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide; and (ii) a first cellular immunity induction promoter.

Abstract translation: 本发明提供了用于诱导细胞免疫的透皮给药的癌症疫苗组合物，其包含（i）HER2 / neu E75肽和/或经修饰的HER2 / neu E75肽; 和（ii）第一细胞免疫诱导启动子。

公开(公告)号：US20140220058A1

公开(公告)日：2014-08-07

申请号：US14166959

申请日：2014-01-29

Applicant: NITTO DENKO CORPORATION

Inventor： Yoshiki MAEDA ,  Katsuyuki OKUBO ,  Daisuke ASARI ,  Arimichi OKAZAKI ,  Takuya SHISHIDO ,  Kyohei MATSUSHITA ,  Wenjing LI ,  Mitsuhiko HORI ,  Haruo SUGIYAMA

IPC: A61K9/00 ,  A61K31/739 ,  A61K31/4745 ,  A61K39/00 ,  A61K38/10

CPC classification number: A61K9/0014 ,  A61K9/006 ,  A61K31/4745 ,  A61K31/739 ,  A61K38/10 ,  A61K39/0011 ,  A61K39/12 ,  A61K2039/54 ,  A61K2039/541 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55572 ,  C12N2770/24234

Abstract: The invention provides a vaccine composition for transdermal or transmucosal administration for inducing cellular immunity, comprising (i) an antigen; and (ii) a pharmacologically acceptable acid or a pharmacologically acceptable salt thereof as a first cellular immunity induction promoter.

Abstract translation: 本发明提供了用于诱导细胞免疫的透皮或经粘膜给药的疫苗组合物，其包含（i）抗原; 和（ii）药理学上可接受的酸或其药理学上可接受的盐作为第一细胞免疫诱导启动子。